2 min read
Unlock the Secrets of Effective SD File Preparation for FDA Submissions
In today's world where digital transformation is reshaping industries, even the pharmaceutical sector is not immune to...
The development of biosimilar products in the U.S. has progressed since the regulatory pathway was established as part of the Affordable Care Act. Since then, the number of active biosimilar development programs has risen steadily. The market for these products is projected to exceed 100 billion dollars by 2028.
Listen to the full episode on Veristat’s Advancing Revolutionary Therapies Podcast to learn more about the analytical and clinical science of biosimilars and their regulatory pathway.
Learning Points
Meet Veristat. Learn More.
2 min read
Sep 20, 2023 Veristat Blog
In today's world where digital transformation is reshaping industries, even the pharmaceutical sector is not immune to...
10 min read
Sep 13, 2023 Veristat Blog
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US...